In conclusion, in this randomized study using PSA doubling time as a surrogate marker for cancer progression, we found no indication that the RhoC-targeting 20mer peptide vaccine was able to delay tumor progression measured as time to PSA doubling, despite inducing a robust CD4+, RhoC-specific immunological reaction. This evidence concerns the gene CD4 and neoplasm.